Protein-Based CXCR3 Antagonists

Autoimmune Diseases. CXCR3 antagonists may have the potential to counteract unwanted immune responses in autoimmune diseases. Here, three examples are highlighted rheumatoid arthritis, multiple sclerosis and Sjogren s syndrome. 

Simultaneous treatment with CXCLll-based antagonist 49 (for definition see Section 13.3.3) and a CXCR4 antagonist blocked experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis. Additional investigations revealed that 49 inhibited the effector phase of the immune response, while the CXCR4 antagonist inhibited the sensitization phase [19]. 

administration of CXCLlO-based antagonist 47 (for definition see Section 13.3.3) to mice reduces the progression of autoimmune sialadenitis, which relates to the inflammation of the sahvary glands as observed in Sjogren s syndrome [17]. 

Transplant Rejection. For quite some time, CXCR3 was assumed to play a key role in 

It is fair to say that the current controversy has led to some tempering of therapeutic hopes for CXCR3 in transplant rejection [105]. 

---